Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Mahidol Oxford Tropical Medicine Research Unit | OTHER |
| Amsterdam UMC, location VUmc | OTHER |
| University Hospital, Antwerp | OTHER |
Not provided
Not provided
Not provided
Not provided
The goal of this woldwide observational study is to investigate various aspects of fluid and vasopressor therapy in critically ill invasively ventilated patients. The main questions it aims to answer are:
Participating intensive care units will gather detailed information about fluid and vasopressor therapy prescribed to participants. Participating intensive care units will also gather information about participant outcomes such as duration of invasive ventilation, length of stay and mortality
Rationale:
The worldwide practice of fluid and vasopressor therapy in critically ill invasively ventilated patients is uncertain. Indeed, it is unclear whether there is a difference in fluid and vasopressor therapy in these patients between Low- and Middle-income Countries (LMICs) and High-income Countries (HICs).
Objective:
To determine various aspects of fluid and vasopressor therapy in critically ill invasively ventilated patients in LMICs and HICs.
Hypothesis:
There is substantial worldwide variation in practice of fluid and vasopressor therapy in critically ill invasively ventilated patients.
Study design:
International, multicenter, observational study in critically ill invasively ventilated patients; data are captured during a predefined period per geographic region or country.
Study population:
Critically ill invasively ventilated patients.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
Because of the observational design of the study using routinely collected data, there is no additional burden for the patient. Collection of data from ICU charts or electronic medical records systems is of no risk to the patients.
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Composite of various aspects of fluid therapy | Including total volumes of types of fluids administered in the first three days after ICU admission and total volume of fluids infused in the first seven days of ICU admission | seven days |
| Measure | Description | Time Frame |
|---|---|---|
| Timing of start of continuous administration of vasopressors. | Timing of start of vasopressors from ICU admission in minutes per administration route (i.e. central versus peripheral) | seven days |
| Duration of vasopressor therapy |
| Measure | Description | Time Frame |
|---|---|---|
| Pre-defined subgroup analysis in patients admitted with burns | All aforementioned outcomes in patients with burns | 90 days |
| Pre-defined subgroup analysis in patients admitted with acute respiratory distress syndrome |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Critically ill invasively ventilated patients that receive ventilation for at least 24 hours.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pieter R. Tuinman, MD | Amsterdam UMC, location VUmc | Principal Investigator |
| Frederique Paulus, Professor | Amsterdam UMC, location AMC | Principal Investigator |
| Marcus J. Schultz, Professor | Mahidol Oxford Tropical Medicine Research Unit | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Amsterdam UMC | Amsterdam | North Holland | Netherlands |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39507456 | Derived | PRoFLUID-Investigators. Practice of Fluid and Vasopressor Therapy in Critically Ill Invasively Ventilated Patients (PRoFLUID)-study protocol for an international multicenter observational cohort study. Ann Transl Med. 2024 Oct 20;12(5):92. doi: 10.21037/atm-23-1957. Epub 2024 Sep 12. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| SAP | No | Yes | No | Statistical Analysis Plan | Sep 21, 2025 | Sep 23, 2025 | SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D016638 | Critical Illness |
| ID | Term |
|---|---|
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
In days
| seven days |
| Types of vasopressors | The type (i.e. noradrenaline, vasopressin, adrenaline) of vasopressors that are prescribed | seven days |
| Concentration of types of vasopressors | The concentration (i.e. in µg/ml) of vasopressors that are prescribed per administration route | seven days |
| Timing of start of administered diuretics. | Time between start of invasive ventilation and administration of diuretics in days | seven days |
| Duration of diuretic therapy | In days | seven days |
| Types of diuretics | The type of diuretics that are prescribed | seven days |
| Bolus or continous infusion of diuretics | seven days |
| Cumulative fluid balances | seven days |
| Daily urine output | seven days |
| Incidence of atrial arrythmias | 7 days |
| Incidence of acute respiratory distress syndrome | 7 days |
| Incidence of renal replacement therapy | 7 days |
| Incidence of need for renal replacement therapy at ICU discharge. | 90 days |
| Typical ICU outcomes; e.g. duration of ventilation, lengths of stay in ICU and hospital and, mortality in the ICU and hospital | 90 days |
All aforementioned outcomes in patients with acute respiratory distress syndrome
| 90 days |
| Pre-defined subgroup analysis in patients admitted with sepsis | All aforementioned outcomes in patients with sepsis | 90 days |